Sellas Life Sciences is trading 10.12% up now at $15.12 after renewed attention to an unconfirmed report that the Phase 3 REGAL leukemia trial reached its prespecified 80th event.
- The company’s latest official update says it will announce when that milestone occurs.
- The previously disclosed official count remained 78 events.
- No confirmed August 27, 2026 company announcement was identified.